Aitia is revolutionizing pharmaceutical R&D with its cutting-edge causal AI-based Gemini Digital Twin platform. Founded in 2010, the company integrates supercomputing capabilities with their proven causal AI reverse-engineering forward-simulation (REFS) engine to construct digital models of human disease biology. These sophisticated in silico tools enhance drug discovery and development processes across the biopharma pipeline, focusing particularly on diseases with significant unmet medical needs in oncological, neuro-degenerative, immunological, and cardiometabolic fields.
By leveraging massive multiomics and clinical datasets, Aitia identifies novel molecular interaction points, thus enabling more precisely targeted therapeutic interventions. The company’s collaborative engagements with biopharmaceutical partners aim to accelerate the development of new therapies.
Their latest funding round, a $28 million Series D investment received on 01 January 2020, was backed by notable investors including Celgene, Cigna Ventures, Echo Health Ventures, and MSD Global Health Innovation Fund.
